Loading stock data…
Capricor Therapeutics, Inc. (CAPR)
$23.80-2.64 (-9.98%)
After Hours$23.93+0.13 (+0.54%)· Last close Jun 29
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Capricor Therapeutics, Inc. in the Healthcare sector is trading at $23.80 with a market capitalization of $1.6B. Wall Street consensus targets $53.60 (10 analysts), implying a +125.2% move over the next 12 months. The stock is currently 41% below its 52-week high of $40.37, remaining 8.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +125.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$36.77M↓ | -$29.16M↓ | -$26.28M↑ | -$27.72M↓ | -$24.98M |
| Net Income | -$33.94M↓ | -$30.17M↓ | -$24.57M↑ | -$25.91M↓ | -$24.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the Un...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.12%
Volume
Today's trading volume
3.22M
Recent News
Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11%
The U.S. Food and Drug Administration will hold an advisory committee meeting to review the biologics license application for Capricor’s DMD therapy on July 29
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%
An oral argument on a dispute between Nippon Shinyaku, its U.S. subsidiary, NS Pharma, and Capricor is scheduled for Wednesday.
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy. Speaking at a Goldman Sac
Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 13, B Riley reiterated a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) with a $63 price target. The positive stance comes as the company enters into a pivotal stage in the potential approval of Deramiocel for the […]
Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus
Capricor Therapeutics (NasdaqGS:CAPR) has filed a lawsuit to rescind its U.S. distribution agreement for deramiocel, its Duchenne muscular dystrophy therapy, with NS Pharma and Nippon Shinyaku. The company argues that flaws in the pricing terms could restrict patient access to deramiocel in the U.S. market. In parallel, Capricor is preparing for potential direct commercialization, including plans to expand manufacturing capacity and strengthen its leadership team. Deramiocel has completed a...